Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

ENSAT Stage I Adrenal Cortex Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 284Specimen Handling 278pembrolizumab 255Cyclophosphamide 234Radiotherapy 224Nivolumab 182Cisplatin 172Biopsy 163Carboplatin 152Radiosurgery 139fludarabine 128Blood Specimen Collection 128Surveys and Questionnaires 117Gemcitabine 117Paclitaxel 114Standard of Care 110venetoclax 109Dexamethasone 103Bevacizumab 96Radiation 92Rituximab 89Oxaliplatin 86Capecitabine 86Cytarabine 85Drug Therapy 83Ipilimumab 81Doxorubicin 81durvalumab 80atezolizumab 74fludarabine phosphate 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ethane × 90 days × Clear all
NCT03583710 2026-04-07

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

M.D. Anderson Cancer Center

Phase 3 Recruiting
240 enrolled

ENSAT Stage I Adrenal Cortex Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡